The Fight Against Prostate Cancer: What Men Need to Know

NEW YORK, Dec. 08, 2016 -- Prostate cancer is the second most common cancer among men, and it is estimated that nearly three million men are living with the disease in the United States. Thankfully, many prostate cancers can be caught early on and either successfully treated or diagnosed as indolent (non-aggressive).

A video accompanying this release is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/571434b2-7e90-4637-8cd0-39c880def041

Early detection of prostate cancer begins with screening the Prostate Specific Antigen (PSA) to assess the health of the prostate. All men should get a PSA test, and know their PSA number and what it means. If a PSA test result is high, often times a doctor may recommend a biopsy. However, because the PSA test cannot distinguish between aggressive prostate cancer and other less serious conditions, many men with a high PSA may be subjected to unnecessary prostate biopsies.

The 4Kscore is a simple blood test that bridges the gap between PSA and biopsy, and can help reduce the need for unnecessary biopsies. The 4Kscore combines four prostate-specific proteins results, including PSA, with clinical information in an algorithm that calculates the man’s percent risk for developing aggressive prostate cancer. In some cases, the 4Kscore will show that the patient is at low risk of aggressive disease and does not need a biopsy. In other cases, the 4Kscore will indicate if the patient is at high risk of aggressive disease and provide additional information that can be used in the shared decision between a patient and his physician about whether to proceed with a biopsy.

The 4Kscore is available at BioReference Laboratories and GenPath Diagnostics, OPKO Health Companies, and is utilized by primary care physicians and urologists across the country.

For more information, visit 4Kscore.com.

Kyle Evans
Rosica Communications
201.843.5600
[email protected]

BioReference Laboratories

BioReference Laboratories, an OPKO Health company, is the third largest full service clinical laboratory in the U.S. providing testing and related services to physician offices, clinics, hospitals, long term care facilities, employers, governmental units and correctional institutions. Our expert division, GenPath Diagnostics, specializes in cancer diagnostics offering a comprehensive cancer patient workup in one laboratory. From special coagulation testing to complex genomic testing for tumor sequencing and hereditary cancer syndromes, the full spectrum of a cancer patient work-up is covered.